Yue Hsin Lin
Founder bij LIN BIOSCIENCE, INC.
Vermogen: 78 M $ op 31-03-2024
Actieve functies van Yue Hsin Lin
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
LIN BIOSCIENCE, INC. | Founder | 12-05-2016 | - |
Chairman | 12-05-2016 | - | |
Investor Relations Contact | 12-05-2016 | - | |
Chief Executive Officer | 01-06-2016 | 01-04-2022 | |
BELITE BIO, INC | Chief Executive Officer | 27-03-2018 | - |
Chairman | 27-03-2018 | - | |
Founder | 27-03-2018 | - | |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The private company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | President | 01-10-2021 | - |
RBP4 Pty Ltd. | Director/Board Member | 01-08-2018 | - |
Chief Executive Officer | 01-04-2021 | - | |
Belite Bio Holdings Corp. | Chief Executive Officer | 01-12-2017 | - |
Chairman | 01-06-2016 | - | |
President | 01-10-2021 | - | |
Belite Bio (HK) Ltd. | Director/Board Member | 01-06-2021 | - |
Loopbaan van Yue Hsin Lin
Eerdere bekende functies van Yue Hsin Lin
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
CVie Therapeutics Ltd.
CVie Therapeutics Ltd. BiotechnologyHealth Technology Founded in 2013, CVie Therapeutics Ltd. is a subsidiary of Windtree Therapeutics, Inc. The private company is based in Taipei, Taiwan. The Taiwanese company develops and researches drugs. | Chief Operating Officer | 01-01-2014 | 01-01-2016 |
President | 01-01-2014 | 01-01-2016 | |
OBI PHARMA, INC. | Chief Tech/Sci/R&D Officer | 01-01-2010 | 01-01-2014 |
ASLAN PHARMACEUTICALS LIMITED | Chief Tech/Sci/R&D Officer | 01-01-2014 | - |
Opleiding van Yue Hsin Lin
The Trustees of Columbia University in The City of New York | Masters Business Admin |
University of Pennsylvania | Undergraduate Degree |
University of Hong Kong | Masters Business Admin |
The University of Sydney | Doctorate Degree |
London Business School | Masters Business Admin |
Statistieken
Internationaal
Verenigde Staten | 6 |
Taiwan | 4 |
Hongkong | 3 |
Operationeel
Chief Executive Officer | 4 |
Chairman | 3 |
Masters Business Admin | 3 |
Sectoraal
Health Technology | 7 |
Consumer Services | 6 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
OBI PHARMA, INC. | Health Technology |
ASLAN PHARMACEUTICALS LIMITED | Health Technology |
LIN BIOSCIENCE, INC. | Health Technology |
BELITE BIO, INC | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
CVie Therapeutics Ltd.
CVie Therapeutics Ltd. BiotechnologyHealth Technology Founded in 2013, CVie Therapeutics Ltd. is a subsidiary of Windtree Therapeutics, Inc. The private company is based in Taipei, Taiwan. The Taiwanese company develops and researches drugs. | Health Technology |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The private company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | Health Technology |
RBP4 Pty Ltd. | |
Belite Bio Holdings Corp. | |
Belite Bio (HK) Ltd. |
- Beurs
- Insiders
- Yue Hsin Lin
- Ervaring